Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-03-19
2009-12-15
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S019300
Reexamination Certificate
active
07632818
ABSTRACT:
The present invention is directed to a method for treating individuals having inflammation or preventing inflammation in individuals at risk for inflammation, more specifically individuals with chronic inflammation as evidenced by elevated C-reactive protein, serum fibrinogen, elevated platelet count and platelet activity, elevated blood glucose, any component or combination of components of the metabolic syndrome by using the selected immunoregulators. The present invention also includes a method for preventing the development of inflammation in individuals at risk for inflammation by using the selected immunoregulators, and for deferring progression of the inflammatory state to the more specific outcomes of the Metabolic Syndrome including diabetes mellitus, coronary heart disease, and cancer.
REFERENCES:
patent: 4127534 (1978-11-01), Coy et al.
patent: 4468379 (1984-08-01), Gottlieb
patent: 4537878 (1985-08-01), Plotnikoff
patent: 4616079 (1986-10-01), Gottlieb
patent: 4699898 (1987-10-01), Gottlieb
patent: 4710380 (1987-12-01), Gottlieb
patent: 4778750 (1988-10-01), Gottlieb
patent: 4874608 (1989-10-01), Gottlieb
patent: 5000936 (1991-03-01), Chibret
patent: 5013546 (1991-05-01), Gottlieb et al.
patent: 5081108 (1992-01-01), Gottlieb
patent: 5093321 (1992-03-01), Gottlieb
patent: 5100663 (1992-03-01), Gottlieb
patent: 6136784 (2000-10-01), L'Italien et al.
patent: 0 230 052 (1986-12-01), None
Persselin et al. Diagnosis of Rheumatoid Arthritis. Clin Orthop Relat Res. 1991. vol. 265, pp. 73-82.
Harris et al. Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care, Apr. 1999. Vol. 21, No. 4, pp. 518-524.
Fletcher et al. Plasma Fibrinogen and the Sedimentation Rate in Rheumatoid Arthritis and their response to the Administration of Cortison and Adrenocorticotropic hormone (ACTH). JCI. Jun. 1952. vol. 31, No. 6, pp. 561-571.
Grundy et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute / American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004:vol. 109, pp. 433-438.
Brennan et al. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Imuunopathol 1998 20: 133-147.
Marise S. Gottlieb et al., “Diabetes Mellitus in Twins”, DIABETES, vol. 17, No. 11, pp.693-704, Nov. 1968.
Ranjana Sinha et al., “Prevalence of Impaired Glucose Tolerance Among Children and Adolescents with Marked Obesity”, The New England Journal of Medicine, vol. 346, No. 11, pp. 802-810, Mar. 14, 2002.
Gary L. Henriksen, “Serum Dioxin and Diabetes Mellitus in Veterans of Operation Ranch Hand”, Epidemiology, vol. 8, No. 3, pp. 252-258, May 1997.
Jean-Charles Schwartz, “Biological Inactivation of Enkephalins and the role of Enkephalin-Dipeptidyl-Carboxypeptidase (“Enkephalinase”) as Neuropeptidase”, Enkephalin Metabolism, vol. 29, No. 17, pp. 1715- 1740, 1981.
Boulos Zacharie et al., “Thioamides: Synthesis Stability, and Immunological Activities of Thianalogues of Imreg. Preparation of New Thiacylating Agents Using Fluorobenzimidazolone Derivatives”, J. Med. Chem. 42, pp. 2046-2052, 1999.
Holger Kayser et al.,“Stimulation of human peripheral blood lymphocytes by bioactive peptides derived from bovine milk proteins”, FEBS Letters 383, pp. 18-20, 1996.
Paul M Ridker et al., “C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events ‘An 8-Year Follow-Up of 14719 Initially Healthy American Women’”, Circulation, 107, pp. 391-397, 2003.
Ripudaman S. Hundal et al., “Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes”, The Journal of Clinical Investigation, vol. 109, No. 10, pp. 1321-1326, May 2002.
Manse S. Gottlieb et al., “Response to Treatment with the Leukocyte-derived Immunomodulator IMREG-1 in Immunocompromised Patients with AIDS-related Complex”, Annals of Internal Medicine, 115, pp. 84-91, 1991.
Bushnell , Esq. Robert E.
Cordero Garcia Marcela M
Tsang Cecilia
LandOfFree
Method for treating conditions associated with the Metabolic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating conditions associated with the Metabolic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating conditions associated with the Metabolic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4114416